According to the Complaint, Exscientia p.l.c. is an AI driven Pharma-tech company that engages in the design and develop differentiated medicines for diseases with high unmet patient needs.

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company's CEO had engaged in improper relationships with employees that were inconsistent with the Company's standards and values; (ii) the Company's Chairman of the Board had prior knowledge of the CEO's relationships and had improperly addressed the misconduct without consulting the Board; (iii) the Company's maintenance and enforcement of its Code of Business Conduct and Ethics was inadequate to safeguard against the foregoing conduct; (iv) the foregoing failures subjected the Company to a heightened risk of disruptive leadership transitions and/or reputational harm; and (v) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.